Trump’s threat to levy steep tariffs on imported generic drugs from mid‑2028 could reshape US pharmaceutical pricing and supply chains
Executive summary: President Donald Trump said he will impose tariffs on generic drug imports beginning August 2028, with an initial rate of 100% that would rise to 200% after one year. The policy would raise the cost of affordable medicines for US patients, pressure generic manufacturers to shift production domestically, risk retaliation, and could lead to WTO litigation.
Who is involved: US President Donald Trump, the Office of the United States Trade Representative, major generic drug firms such as Teva Pharmaceutical Industries, Sandoz (Novartis) and Mylan, US healthcare payers and patients.
Likely next: Administration officials will draft the tariff schedule, industry groups will lobby for exemptions or delays, and affected countries may file complaints at the World Trade Organization.
The announcement mirrors previous protectionist moves by the administration, targeting foreign‑made generics to push domestic production. If implemented, the tariffs would start at 100% and double after a year, imposing a substantial cost increase on low‑cost medicines. Analysts warn the measure could trigger trade disputes and incentivize companies to relocate manufacturing to the United States.
Timeline
- — US-Zölle: Trump droht mit Zöllen auf Arznei-Generika ab Sommer 2028 (Handelsblatt)
- — Trump says he will impose tariffs on generic drugs starting in August 2028 (Politico Europe)
Analysis — what this means
Likely next events
- August 1, 2028 – scheduled start date for 100% tariff on generic drug imports
- August 1, 2029 – planned increase to 200% tariff
- Q4 2026 – expected release of detailed tariff proposal by USTR
- Early 2027 – potential WTO consultation request by EU or India
Sectors affected
- generic pharmaceutical manufacturing
- US drug import and distribution
- active pharmaceutical ingredient (API) suppliers
Regulatory implications
- USTR investigation under Section 301 of the Trade Act of 1974 to justify tariffs
- Possible WTO dispute settlement proceeding alleging violation of TRIPS and MFN principles
- Congressional oversight hearings on drug pricing impacts
Historical parallels
- US Section 301 tariffs on Chinese solar panels (2012) that raised import costs
- 2018 US steel and aluminum tariffs (25% and 10%) that prompted WTO cases
- 2020 EU antidumping duties on Chinese generic APIs